Massachusetts Wealth Management Buys 190 Shares of Invesco Biotechnology & Genome ETF $PBE

Massachusetts Wealth Management grew its holdings in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 1.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,394 shares of the company’s stock after purchasing an additional 190 shares during the period. Massachusetts Wealth Management owned about 0.53% of Invesco Biotechnology & Genome ETF worth $1,179,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PBE. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Invesco Biotechnology & Genome ETF by 10.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,066 shares of the company’s stock valued at $271,000 after purchasing an additional 390 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Invesco Biotechnology & Genome ETF by 256.8% in the first quarter. Farther Finance Advisors LLC now owns 8,616 shares of the company’s stock valued at $535,000 after purchasing an additional 6,201 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Invesco Biotechnology & Genome ETF by 12.5% in the first quarter. Janney Montgomery Scott LLC now owns 5,424 shares of the company’s stock valued at $344,000 after purchasing an additional 604 shares during the last quarter. Millstone Evans Group LLC raised its holdings in shares of Invesco Biotechnology & Genome ETF by 75.8% in the first quarter. Millstone Evans Group LLC now owns 1,684 shares of the company’s stock valued at $107,000 after purchasing an additional 726 shares during the last quarter. Finally, Banque Cantonale Vaudoise acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the first quarter valued at approximately $34,000.

Invesco Biotechnology & Genome ETF Stock Up 0.2%

NYSEARCA PBE opened at $72.05 on Thursday. Invesco Biotechnology & Genome ETF has a 12-month low of $54.52 and a 12-month high of $73.03. The company has a market capitalization of $226.24 million, a PE ratio of 20.44 and a beta of 0.87. The firm’s 50 day moving average is $68.91 and its 200-day moving average is $64.99.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.